Divesiran is a first-in-class siRNA therapy in clinical development for PV,
with best-in-class potential. PV is a chronic myeloproliferative neoplasm ─ a type of rare blood cancer
─ characterized by the excessive production of red blood cells, which can be associated with a higher
rate of death from cardiovascular and thrombotic events.
Discovered through the Silence mRNAi GOLD™ platform, divesiran is designed to selectively silence
TMPRSS6, a gene involved in regulating hepcidin, the body’s key regulator of iron metabolism. By
increasing hepcidin levels, divesiran aims to limit iron availability for red blood cell production,
helping to control hematocrit levels and potentially reducing the need for frequent therapeutic
phlebotomies.
Results from the Phase 2 SANRECO study of divesiran in phlebotomy-dependent PV
patients support a potentially best-in-class profile with once-every-three-month dosing. A Phase 3 study
is planned for 2027.
Learn More About the SANRECO
Study
Learn More
About PV